BX-795

For research use only.

Catalog No.S1274

33 publications

BX-795 Chemical Structure

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 200 In stock
USD 150 In stock
USD 320 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's BX-795 has been cited by 33 publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.
Targets
PDK-1 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
CDK2/CyclinE [1]
(Cell-free assay)
Chk1 [1]
(Cell-free assay)
6 nM 320 nM 430 nM 510 nM
In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. [1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. [2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV-4-11 cell M{j2T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjKflVKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Pi56IH7N NH7TN|FUSU6JRWK=
KRX cells MYjGeY5kfGmxbjDhd5NigQ>? M13RVVchdWmwcx?= NWO3cFJxUW6qaXLpeIlwdiCxZjDTWW1QNXSjZ3fl[EBWVEtzIDj1cotvd3ewIH;ybYdqdilia3nuZZNmKGSxbXHpckBmgHC{ZYPz[YQhcW5iS2LYJINmdGy|IIXzbY5oKFt|MmDdMYdidW2jLVHUVEBidmRibYnlcIlvKGKjc3njJJBzd3SnaX6gd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiNzDtbY5{ MkjaNlYzPzV4OEG=
human NKM-1 cell NHvJZppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPPZ3JKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjF7NDFOwG0> NF7rRVFUSU6JRWK=
human P30-OHK cell NGnISWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NI\DWG9KdmirYnn0bY9vKG:oIHj1cYFvKFB|MD3PTGsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTygTWM2OD1yLkS5OlUh|ryP MnXEV2FPT0WU
human YH-13 cell MkCyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M321S2lvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzQDh6IN88US=> NFn0SFFUSU6JRWK=
human LXF-289 cell MnLrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU4hUUN3ME2wMlY2Pjl|IN88US=> MVnTRW5ITVJ?
human BE-13 cell NVOweJVKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3joUmlvcGmkaYTpc44hd2ZiaIXtZY4hSkVvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcxPDd5IN88US=> MXnTRW5ITVJ?
human RS4-11 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYfJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|I2QTRizszN NWflbYhEW0GQR1XS
human A3-KAW cell NHm2UFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHHkPWVKdmirYnn0bY9vKG:oIHj1cYFvKEF|LVvBW{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzNyNUWg{txO NHW5TnVUSU6JRWK=
human PA-1 cell M{Oze2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlLPTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64NFQzOiEQvF2= MnvhV2FPT0WU
human ES7 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NU\Y[Vg5UW6qaXLpeIlwdiCxZjDoeY1idiCHU{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg{PTZ4IN88US=> M3;XNXNCVkeHUh?=
human ES8 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHjTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0N|M3KM7:TR?= NIDocYVUSU6JRWK=
human SW982 cell NYq4ZWVjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUjJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OVEzPCEQvF2= MYrTRW5ITVJ?
human VA-ES-BJ cell NFrtOXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDGTY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTh2Nkeg{txO Mn\QV2FPT0WU
human 697 cell NVnaOGdkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMEG2NlMh|ryP NELV[IxUSU6JRWK=
human MOLT-4 cell MlvpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHzJbHRKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODN{NESg{txO MXjTRW5ITVJ?
human D-283MED cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEL6OmZKdmirYnn0bY9vKG:oIHj1cYFvKERvMkizUWVFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yM{m0PEDPpG1? MkPiV2FPT0WU
human ALL-PO cell MljkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkXBTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA3ODd|IN88US=> NFv0dolUSU6JRWK=
human NB14 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnLHTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wOlA5OSEQvF2= NHy2d|hUSU6JRWK=
human NTERA-S-cl-D1 cell NYnrSnFNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF3j[pZKdmirYnn0bY9vKG:oIHj1cYFvKE6WRWLBMXMu[2xvREGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA4Pzd3IN88US=> NGnxbndUSU6JRWK=
human BFTC-905 cell NXS1dFdTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXPkXVY4UW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMEixNFEh|ryP MmP2V2FPT0WU
human H4 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmfCTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMUCyNFEh|ryP NV[3VFB2W0GQR1XS
human CHP-212 cell M3fkUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVe1VYozUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNECzO{DPxE1? MUPTRW5ITVJ?
human A204 cell NVq0UmMxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmXVTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xOVQ3PyEQvF2= MmfKV2FPT0WU
human NB69 cell Ml\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{L5fWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVU5PjVizszN MYXTRW5ITVJ?
human P12-ICHIKAWA cell M1rXUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1\jcGlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xPFE4OSEQvF2= MXPTRW5ITVJ?
human L-363 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NInZRXZKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yQDF7NzFOwG0> NXf6dGJNW0GQR1XS
human ES5 cell NEHGWGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PUTGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xPVM2PCEQvF2= NXzCU4syW0GQR1XS
human CAL-51 cell NX;uWmJZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NET1TGtKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjJzNU[g{txO NInU[mxUSU6JRWK=
human NBsusSR cell NGG3UGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHOzXHBKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ2NUe4JO69VQ>? NEW5VVdUSU6JRWK=
human HOP-92 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTWSYlKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD25NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjd{OUOg{txO NFPkWXlUSU6JRWK=
human DU-4475 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI6OjR3IN88US=> Mn\0V2FPT0WU
human LB1047-RCC cell Ml[xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ7MkixJO69VQ>? NVPIXJNZW0GQR1XS
human D-566MG cell MnnvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFi2[XJKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyNES4JO69VQ>? Mk\yV2FPT0WU
human A375 cell MmjpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHfpVnJKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMxQDV6IN88US=> MXzTRW5ITVJ?
human ATN-1 cell Mn;nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4jsdmlvcGmkaYTpc44hd2ZiaIXtZY4hSVSQLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM4OTh3IN88US=> NIXOU3JUSU6JRWK=
human M059J cell NILiSY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkP6TY5pcWKrdHnvckBw\iCqdX3hckBOODV7SjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|c3PTJizszN M3\w[XNCVkeHUh?=
human HSC-3 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OFIxQCEQvF2= NWf4b2RPW0GQR1XS
human DOHH-2 cell M4jK[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1\MNGlvcGmkaYTpc44hd2ZiaIXtZY4hTE:KSD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PThzNDFOwG0> NYXkO25pW0GQR1XS
human G-402 cell M3;GeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmXBTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFY2OjVizszN Moi3V2FPT0WU
human LC-2-ad cell MkL6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPzV5pDUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2yMYFlKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52N{GzNkDPxE1? M13JUnNCVkeHUh?=
human LOXIMVI cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;nXopKdmirYnn0bY9vKG:oIHj1cYFvKEyRWFnNWmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjVyNUWyJO69VQ>? M4T4VnNCVkeHUh?=
human DK-MG cell MnLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYLEfphZUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTd{OUig{txO NX3xbI9vW0GQR1XS
human HOS cell NH3nbZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFTjZVFKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVc{ODlizszN NF71eZlUSU6JRWK=
human BHT-101 cell MoDqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mm\rTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42Pzh5NzFOwG0> M4LrR3NCVkeHUh?=
human U-2-OS cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnPOTY5pcWKrdHnvckBw\iCqdX3hckBWNTJvT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU5QDB4IN88US=> NEG2XGZUSU6JRWK=
human D-423MG cell NHuwfG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEnjOJlKdmirYnn0bY9vKG:oIHj1cYFvKERvNEKzUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZyOEC2JO69VQ>? M1X4TnNCVkeHUh?=
human AN3-CA cell Ml7VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1nUdGlvcGmkaYTpc44hd2ZiaIXtZY4hSU5|LVPBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Ozl7MTFOwG0> MnK4V2FPT0WU
human TE-11 cell M2\BcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHCNGFDUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV{ODFOwG0> NEXsXZRUSU6JRWK=
human SK-NEP-1 cell NFTXTlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mme5TY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV|N{[g{txO NEn6TYRUSU6JRWK=
human MG-63 cell M2CwR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVzJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62PFU3PyEQvF2= M{\iNXNCVkeHUh?=
human RH-1 cell NYfWUVVoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHJJNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkewNlc1KM7:TR?= MYrTRW5ITVJ?
human MDA-MB-157 cell M3rTWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4Pz[mlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwN{G2O|Qh|ryP MVzTRW5ITVJ?
human A427 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkezOVg6KM7:TR?= NHjqXmtUSU6JRWK=
human ES1 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwN{W0OVEh|ryP NVOxOo1CW0GQR1XS
human C32 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTyXVdKdmirYnn0bY9vKG:oIHj1cYFvKEN|MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|Y{QSEQvF2= NUf2RoR5W0GQR1XS
human LAMA-84 cell NGS4ZW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVrKSVN2UW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55Nki3NkDPxE1? NFfBbIRUSU6JRWK=
human YKG-1 cell NV7xNnZqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGPsUolKdmirYnn0bY9vKG:oIHj1cYFvKFmNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PzF{NDFOwG0> MV3TRW5ITVJ?
human NCI-H1048 cell NWm2eIZiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmHLTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwOFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjd6NUC5JO69VQ>? NF64bJlUSU6JRWK=
human KS-1 cell M{C3fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfoSHlKdmirYnn0bY9vKG:oIHj1cYFvKEuVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlgzQThizszN NYDkeo01W0GQR1XS
human JVM-3 cell NUfHdFF1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFLabI5KdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PjR7MTFOwG0> NFnlR5BUSU6JRWK=
human GI-ME-N cell NF3ObGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;zRWVQUW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NkWzJO69VQ>? NFPaZ3RUSU6JRWK=
human GT3TKB cell NF3tVnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGdVO1SNQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFk3PDJizszN MoHZV2FPT0WU
human CHL-1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65NlM4QSEQvF2= MXPTRW5ITVJ?
human CHP-134 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWLNNWI{UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNVM1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57NES2O{DPxE1? M1HIcHNCVkeHUh?=
human 8-MG-BA cell M4ewdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVfJcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2PzR2IN88US=> NGHvVoJUSU6JRWK=
human HO-1-N-1 cell NFfsVo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGjT[4pKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57N{GxO{DPxE1? MoLxV2FPT0WU
human SW1088 cell MlnvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWnEcXdvUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl7NkezJO69VQ>? M1HPenNCVkeHUh?=
human SW48 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkCyNFY4KM7:TR?= NYK2SnJmW0GQR1XS
human VM-CUB-1 cell M3XTOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoPWTY5pcWKrdHnvckBw\iCqdX3hckBXVS2FVVKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODRzMUmg{txO MkPwV2FPT0WU
human COLO-800 cell NEPK[nBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXLUdpBGUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVgxOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMEWxN|Yh|ryP NWDvV25[W0GQR1XS
human TI-73 cell NXqxOZBvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUS4VXZ7UW6qaXLpeIlwdiCxZjDoeY1idiCWST23N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTF|OUmg{txO Mor6V2FPT0WU
human HN cell NF\aXppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXwTY5pcWKrdHnvckBw\iCqdX3hckBJViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMUKxPVgh|ryP MnHMV2FPT0WU
human DB cell MoPOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXXNTGhCUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVI3OzFizszN MX\TRW5ITVJ?
human Ca9-22 cell M4XYOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoTVTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlEzQDR5IN88US=> NGW0TmlUSU6JRWK=
human A549 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFi4PJpKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlE{QDB6IN88US=> MWLTRW5ITVJ?
human KGN cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4LhUGlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNlU6PSEQvF2= NFzz[Y9USU6JRWK=
human BCPAP cell NXXIXpJGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NELDUo1KdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zOzF3ODFOwG0> NULzcll[W0GQR1XS
human Ramos-2G6-4C10 cell Mn\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHKycm9KdmirYnn0bY9vKG:oIHj1cYFvKFKjbX;zMVJIPi12Q{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zOzd3OTFOwG0> NHnCPFhUSU6JRWK=
human OVCAR-5 cell MmDyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk[4TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zPzd|NDFOwG0> MXHTRW5ITVJ?
human KG-1 cell NHnZXJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXSTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yO|c6OiEQvF2= MmLHV2FPT0WU
human CAKI-1 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrZTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5ODV6IN88US=> MnfXV2FPT0WU
human QIMR-WIL cell NFzBbotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWPjNIw6UW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMki3OFQh|ryP M3G3U3NCVkeHUh?=
human SW1710 cell M37DUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYexNpJiUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ7MUSyJO69VQ>? NH7J[GhUSU6JRWK=
human SK-UT-1 cell M2nJ[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\vcXFKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ7M{O5JO69VQ>? MVnTRW5ITVJ?
human IST-SL1 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlnzTY5pcWKrdHnvckBw\iCqdX3hckBKW1RvU1yxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{OjF5NDFOwG0> MWXTRW5ITVJ?
human SW962 cell Moj5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2j2cWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM{PzV5IN88US=> NXX4dZh4W0GQR1XS
human EM-2 cell NHjsXJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvHPFA5UW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{PTN|NzFOwG0> NVrT[JM6W0GQR1XS
human D-263MG cell NWLtclhUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmPOTY5pcWKrdHnvckBw\iCqdX3hckBFNTJ4M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDN{NzFOwG0> NIDs[WtUSU6JRWK=
human T98G cell NHOzPWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3H6V2lvcGmkaYTpc44hd2ZiaIXtZY4hXDl6RzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|g5PTdizszN NULqSlU4W0GQR1XS
human CTB-1 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4TBZ2lvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM6PzZzIN88US=> NV\LOlVDW0GQR1XS
human Hs-578-T cell M3LSfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3v4WGlvcGmkaYTpc44hd2ZiaIXtZY4hUHNvNUe4MXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjRzNUi3JO69VQ>? NUfUPZRsW0GQR1XS
human SF126 cell NV7lc3NGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj60N|YzOSEQvF2= M3XNXXNCVkeHUh?=
human NCI-H460 cell NYXaXVI3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41Ozl3NTFOwG0> MX7TRW5ITVJ?
human NCI-H1755 cell MkHkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vGfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53NEC0N{DPxE1? NUjDcFJRW0GQR1XS
human HL-60 cell M3n3OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1zOPGlvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU1OTV7IN88US=> MWXTRW5ITVJ?
human G-401 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3YTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVYxQTlizszN MnfXV2FPT0WU
human AGS cell M2rjSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3nKV2lvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61OlI2PyEQvF2= MWDTRW5ITVJ?
human HuO9 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWrVNWpDUW6qaXLpeIlwdiCxZjDoeY1idiCKdV:5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42PjR3NjFOwG0> NWDV[VdYW0GQR1XS
human MFE-280 cell NXrtTHVYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmrwTY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42PjZ6NjFOwG0> NYTVUGpjW0GQR1XS
human NCI-H292 cell NIPjcmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXfzcHpHUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUe3NlIh|ryP MV3TRW5ITVJ?
human HuO-3N1 cell NWHzWpJVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnlV2NYUW6qaXLpeIlwdiCxZjDoeY1idiCKdV:tN24yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MEOwO{DPxE1? M1HZSXNCVkeHUh?=
human ES3 cell Mnv6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF;KTWFKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOlIzQDVizszN M3fsXXNCVkeHUh?=
human LB2241-RCC cell NIe0[JJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjJ2MT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZ7MEe5JO69VQ>? M1TmcXNCVkeHUh?=
human NCI-H1155 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NETmTGRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVE2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNkm0NFUh|ryP Mn7MV2FPT0WU
human SW872 cell NHjMdVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1z6dmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlcxPjd4IN88US=> MX\TRW5ITVJ?
human MHH-ES-1 cell M4HSVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXPEN|NSUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwN{K2N|Mh|ryP MYnTRW5ITVJ?
human KYSE-150 cell M1T5OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1roZ2lvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT2xOVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjd{OUeg{txO MoPsV2FPT0WU
human MC-IXC cell Mk\3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFk2OyEQvF2= MXvTRW5ITVJ?
human HCC1187 cell MoLSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF[wcmhKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GxPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjh7Nke3JO69VQ>? M3fkT3NCVkeHUh?=
human UMC-11 cell M3r3[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJHVOSy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVA1PzdizszN MmfYV2FPT0WU
human NB5 cell NX3veFVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH;LXndKdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVM4OTVizszN NHHQZZNUSU6JRWK=
human A2058 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnz1TY5pcWKrdHnvckBw\iCqdX3hckBCOjB3ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVc5PDRizszN NEfFXpBUSU6JRWK=
human Becker cell NF30NHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7tTY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAyOTF{IN88US=> NIPJPVdUSU6JRWK=
human CAS-1 cell MlHhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEfkWGdKdmirYnn0bY9vKG:oIHj1cYFvKEODUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOTV4OTFOwG0> NEC1RmlUSU6JRWK=
human SW780 cell NUfxbZF1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1mw[2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI2PjB7IN88US=> NXLzfGdMW0GQR1XS
human KM12 cell NVj1eWFOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn[5TY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6zNFE{OiEQvF2= NGO1PIxUSU6JRWK=
human PC-3 cell M3m3NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mni0TY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xO|QyOSEQvF2= M{fyO3NCVkeHUh?=
human A253 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG4PFk{KM7:TR?= MXvTRW5ITVJ?
human NB10 cell NIPIc3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlyxTY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6yNlc4OyEQvF2= NHyxb29USU6JRWK=
human A172 cell NFfO[mxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGS5OHBKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ1PTdizszN MlXoV2FPT0WU
human A498 cell MnTyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1[2VmlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOVY{QDNizszN M{DGRXNCVkeHUh?=
human SW1573 cell M{Hkb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXXPN4JWUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G1O|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjlyNEmxJO69VQ>? MYjTRW5ITVJ?
human 5637 cell MmTDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXvJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkC3PVA1KM7:TR?= Mmj1V2FPT0WU
human A388 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLrSpZKdmirYnn0bY9vKG:oIHj1cYFvKEF|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4yOzl6IN88US=> M4fKSHNCVkeHUh?=
human U251 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PsTmlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlEyPzVizszN NVT3NXNPW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-p38 / p38 / p-JNK / JNK / gD-2 ; 

PubMed: 28112176     


BX-795 inhibition on HSV replication attenuated by overexpression of p38/JNK. HeLa cells with or without JNK1 or p38 overexpression were infected with HSV-2 and total cellular protein was prepared for WB analysis. gD-2, the phosphorylation level of p38 MA䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘

pTBK1 / TBK1 / pPLK1 / PLK1; 

PubMed: 26772203     


TBK1 mediated activation of the mitotic kinase PLK1. SW210.5 cells were treated with indicated TBK1 inhibitors for 1 hour and then exposed to 50 ng/mL of nocodazole for 18 hours. Western blot detected the signaling change using indicated antibodies, and β䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

28112176 26772203
Growth inhibition assay
Cell viability ; 

PubMed: 26772203     


Four SCLC cell lines with no MYC amplification were treated with TBK1 inhibitor BX-795 at the titration concentration. Cell viability was performed by CellTiter Glo 4 days after treatment. The growth curve was constructed by GraphPad Prism 6. 

26772203

Protocol

Kinase Assay:[1]
- Collapse

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
  • Concentrations: ~10 μM
  • Incubation Time: 72 hours
  • Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.07 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG +2% Tween 80+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 591.47
Formula

C23H26IN7O2S

CAS No. 702675-74-9
Storage powder
in solvent
Synonyms N/A
Smiles IC1=CN=C(NC2=CC(=CC=C2)NC(=O)N3CCCC3)N=C1NCCCNC(=O)C4=CC=CS4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S1274 for animal studies?

  • Answer:

    We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products

Tags: buy BX-795|BX-795 ic50|BX-795 price|BX-795 cost|BX-795 solubility dmso|BX-795 purchase|BX-795 manufacturer|BX-795 research buy|BX-795 order|BX-795 mouse|BX-795 chemical structure|BX-795 mw|BX-795 molecular weight|BX-795 datasheet|BX-795 supplier|BX-795 in vitro|BX-795 cell line|BX-795 concentration|BX-795 nmr|BX-795 in vivo|BX-795 clinical trial|BX-795 inhibitor|BX-795 PI3K/Akt/mTOR inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID